Trending Stock News

Pzena Investment Management Raised Its Ply Gem Holdings (PGEM) Position; SWEDISH ORPHAN BIOVI (BIOVF) Shorts Raised By 18.05%

Pzena Investment Management Llc increased Ply Gem Holdings Inc (PGEM) stake by 127.1% reported in 2017Q3 SEC filing. Pzena Investment Management Llc acquired 1.09M shares as Ply Gem Holdings Inc (PGEM)’s stock declined 2.57%. The Pzena Investment Management Llc holds 1.95M shares with $33.29M value, up from 859,716 last quarter. Ply Gem Holdings Inc now has $1.25B valuation. The stock increased 1.11% or $0.2 during the last trading session, reaching $18.2. About 67,709 shares traded. Ply Gem Holdings, Inc (NYSE:PGEM) has risen 22.22% since January 14, 2017 and is uptrending. It has outperformed by 5.52% the S&P500.

SWEDISH ORPHAN BIOVI (OTCMKTS:BIOVF) had an increase of 18.05% in short interest. BIOVF’s SI was 1.77 million shares in January as released by FINRA. Its up 18.05% from 1.50 million shares previously. It closed at $14.7195 lastly. It is down 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Investors sentiment increased to 1.48 in Q3 2017. Its up 0.38, from 1.1 in 2017Q2. It is positive, as 16 investors sold PGEM shares while 28 reduced holdings. 24 funds opened positions while 41 raised stakes. 19.91 million shares or 1.94% less from 20.31 million shares in 2017Q2 were reported. Schwab Charles Investment Mgmt owns 270,193 shares or 0% of their US portfolio. 782,102 are owned by Walthausen Company Ltd Llc. Bowling Portfolio Mngmt Ltd Liability Corp accumulated 0.13% or 49,555 shares. Millennium Limited Liability stated it has 151,493 shares. Putnam Invests Limited Liability has 0% invested in Ply Gem Holdings, Inc (NYSE:PGEM) for 40,675 shares. Moreover, Menta Cap Limited Liability Corporation has 0.1% invested in Ply Gem Holdings, Inc (NYSE:PGEM) for 38,779 shares. American Group invested 0% of its portfolio in Ply Gem Holdings, Inc (NYSE:PGEM). Moreover, Morgan Stanley has 0% invested in Ply Gem Holdings, Inc (NYSE:PGEM). Numeric Limited Liability Company owns 52,161 shares. Dreman Value L L C owns 665 shares. Wells Fargo & Mn accumulated 28,134 shares. Pzena Invest Mngmt Ltd Limited Liability Company, New York-based fund reported 1.95M shares. D E Shaw And reported 108,547 shares stake. Glenmede Trust Na has invested 0% in Ply Gem Holdings, Inc (NYSE:PGEM). Dimensional Fund Limited Partnership holds 0.01% of its portfolio in Ply Gem Holdings, Inc (NYSE:PGEM) for 1.09M shares.

Pzena Investment Management Llc decreased On Semiconductor Corp (ONNN) stake by 3.13 million shares to 5.79M valued at $106.88 million in 2017Q3. It also reduced Stanley Black & Decker Inc (NYSE:SWK) stake by 367,280 shares and now owns 868,306 shares. Allstate Corp (NYSE:ALL) was reduced too.

Among 7 analysts covering Ply Gem Holdings (NYSE:PGEM), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Ply Gem Holdings had 19 analyst reports since August 11, 2015 according to SRatingsIntel. As per Tuesday, September 19, the company rating was maintained by KeyBanc Capital Markets. The rating was maintained by RBC Capital Markets on Monday, July 24 with “Buy”. The stock has “Buy” rating by RBC Capital Markets on Monday, June 19. The rating was maintained by RBC Capital Markets with “Buy” on Tuesday, August 8. The rating was upgraded by Zelman to “Buy” on Tuesday, March 14. RBC Capital Markets maintained the stock with “Buy” rating in Monday, September 11 report. The firm has “Buy” rating by RBC Capital Markets given on Tuesday, November 7. As per Tuesday, August 11, the company rating was maintained by Deutsche Bank. The rating was maintained by KeyBanc Capital Markets on Tuesday, October 24 with “Hold”. The rating was maintained by Imperial Capital with “Outperform” on Tuesday, August 11.

Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, makes, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Sweden and internationally. The company has market cap of $. The Company’s core products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; and Xiapex for the treatment of DupuytrenÂ’s contracture and PeyronieÂ’s disease. It has a 36.89 P/E ratio. The firm also offers Elocta and Alprolix for the treatment of haemophilia; and Ammonaps, Ammonul, and Ravicti for use in the genetics and metabolism diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *